Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Edgewise Therapeutics Inc's Business Segments
Edgewise Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Single Reportable Segment
Total Revenue
-
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Single Reportable Segment0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Single Reportable Segment | - | - |
Annual Results
Revenue Share by Reportable Segment - FY
- Single Reportable Segment0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Single Reportable Segment | - | - |
Description of Edgewise Therapeutics Inc
Edgewise Therapeutics is a pharmaceutical company that is focused on the development of muscle-specific drugs. The company has a platform technology that allows it to create drugs that target specific muscles, which can help address debilitating diseases and conditions that affect the musculature system.
The company’s lead drug candidate is called EDG-5506, which is being developed for the treatment of Duchenne Muscular Dystrophy (DMD). DMD is a genetic disorder that causes muscle degeneration and weakness, affecting around 1 in every 3,500 boys worldwide. There is currently no cure for the disease, and existing treatments only help manage the symptoms.
EDG-5506 works by inhibiting the activity of enzymes that are responsible for breaking down and degrading a protein called dystrophin, which is crucial for healthy muscle function. By blocking these enzymes, the drug can increase the production and availability of dystrophin, which can help improve muscle strength and function in patients with DMD.
In addition to its lead program in DMD, Edgewise Therapeutics is also working on developing drugs for other muscle-specific disorders, including facioscapulohumeral muscular dystrophy (FSHD), limb-girdle muscular dystrophy (LGMD), and Becker muscular dystrophy (BMD). The company’s platform technology allows it to target these specific muscles with precision, which can increase the efficacy and safety of its drugs.
Edgewise Therapeutics was founded in 2017 and is headquartered in Boulder, Colorado. The company has raised over $127 million in funding to date, including a $95 million Series B funding round in 2020 led by Sofinnova Investments and RA Capital Management. The company’s management team includes experienced industry veterans with backgrounds in drug development, clinical research, and business development.
The company’s lead drug candidate is called EDG-5506, which is being developed for the treatment of Duchenne Muscular Dystrophy (DMD). DMD is a genetic disorder that causes muscle degeneration and weakness, affecting around 1 in every 3,500 boys worldwide. There is currently no cure for the disease, and existing treatments only help manage the symptoms.
EDG-5506 works by inhibiting the activity of enzymes that are responsible for breaking down and degrading a protein called dystrophin, which is crucial for healthy muscle function. By blocking these enzymes, the drug can increase the production and availability of dystrophin, which can help improve muscle strength and function in patients with DMD.
In addition to its lead program in DMD, Edgewise Therapeutics is also working on developing drugs for other muscle-specific disorders, including facioscapulohumeral muscular dystrophy (FSHD), limb-girdle muscular dystrophy (LGMD), and Becker muscular dystrophy (BMD). The company’s platform technology allows it to target these specific muscles with precision, which can increase the efficacy and safety of its drugs.
Edgewise Therapeutics was founded in 2017 and is headquartered in Boulder, Colorado. The company has raised over $127 million in funding to date, including a $95 million Series B funding round in 2020 led by Sofinnova Investments and RA Capital Management. The company’s management team includes experienced industry veterans with backgrounds in drug development, clinical research, and business development.
Edgewise Therapeutics Inc. - Comprehensive Overview
1. Segments:
Edgewise Therapeutics Inc. operates primarily within the biotechnology and pharmaceutical sectors, with a concentrated focus on neuromuscular diseases. The companys strategic direction is driven by the urgent need for effective treatments for these serious muscle disorders, particularly those that significantly impair the quality of life for affected individuals. The growing prevalence of such conditions, coupled with increasing advancements in drug development technology, positions Edgewise Therapeutics in a vital and expanding therapeutic landscape.
A key segment of Edgewise relates to the R&D (Research and Development) of novel therapeutic solutions. The company invests heavily in scientific research to explore new drug candidates, aiming to distinguish themselves through innovative approaches that specifically target the biological mechanisms of muscle disorders. By concentrating on the science of small molecule therapies, Edgewise is positioned to create solutions that address both the symptoms and the root causes of neuromuscular diseases.
2. Products:
The flagship product in the Edgewise pipeline is EGW-2102, a pioneering small molecule therapy designed to treat Duchenne Muscular Dystrophy (DMD), a severe and progressive muscle degeneration condition affecting primarily male children. EGW-2102 is characterized by its mechanism of action, which focuses on restoring and expanding the expression of functional dystrophin, a protein essential for muscle cell integrity. The lack of dystrophin in DMD leads to progressive muscle weakness and decline, underscoring the potential impact of this treatment.
EGW-2102 is currently undergoing Phase 1 clinical trials, a critical step in evaluating its safety, tolerability, and preliminary efficacy in patients with DMD. The outcomes of these trials will be pivotal for advancing to subsequent phases of clinical development. If successful, EGW-2102 could not only serve DMD patients but may also be applicable to other muscle disorders characterized by dystrophin deficiency or dysfunction.
In addition to EGW-2102, Edgewise Therapeutics is actively investigating other drug candidates within its pipeline, centralizing its research efforts on conditions that lack effective treatments and are underserved by existing therapeutics.
3. Services:
In its mission to bring new therapies to market, Edgewise Therapeutics provides a range of services that leverage its scientific expertise and proprietary platforms. These services include:
- Drug Discovery and Development: Utilizing advanced methodologies, the company focuses on identifying and developing small molecule candidates targeting muscle disorders. This involves comprehensive screening processes to assess biological activity, selectivity, and other pharmacological properties of potential therapeutic agents.
- Pre-Clinical Research Services: Edgewise conducts rigorous pre-clinical studies to evaluate the efficacy, safety, and pharmacokinetics of their drug candidates. This encompasses both in-vitro assays, which involve testing the compounds in controlled laboratory environments, and in-vivo studies, where the effects of the drugs are observed in live animal models.
- Collaborations and Partnerships: The company actively seeks collaborations with academic institutions and private sector partners to enhance its research capabilities and expand its product pipeline. These partnerships may involve joint ventures in drug development, sharing of technologies, and combined clinical trials.
- Consultative Services: Leveraging its industry knowledge, Edgewise Therapeutics may offer consultative support to other biotechnology and pharmaceutical companies aiming to navigate the complexities of drug development for neuromuscular diseases.
In summary, Edgewise Therapeutics Inc. is dedicated to pioneering small molecule therapies aimed at transforming the treatment landscape for neuromuscular diseases. With EGW-2102 as a central focus and a commitment to collaborative research and development efforts, the company seeks to deliver meaningful advancements that can significantly enhance the lives of patients suffering from debilitating muscle disorders.
1. Segments:
Edgewise Therapeutics Inc. operates primarily within the biotechnology and pharmaceutical sectors, with a concentrated focus on neuromuscular diseases. The companys strategic direction is driven by the urgent need for effective treatments for these serious muscle disorders, particularly those that significantly impair the quality of life for affected individuals. The growing prevalence of such conditions, coupled with increasing advancements in drug development technology, positions Edgewise Therapeutics in a vital and expanding therapeutic landscape.
A key segment of Edgewise relates to the R&D (Research and Development) of novel therapeutic solutions. The company invests heavily in scientific research to explore new drug candidates, aiming to distinguish themselves through innovative approaches that specifically target the biological mechanisms of muscle disorders. By concentrating on the science of small molecule therapies, Edgewise is positioned to create solutions that address both the symptoms and the root causes of neuromuscular diseases.
2. Products:
The flagship product in the Edgewise pipeline is EGW-2102, a pioneering small molecule therapy designed to treat Duchenne Muscular Dystrophy (DMD), a severe and progressive muscle degeneration condition affecting primarily male children. EGW-2102 is characterized by its mechanism of action, which focuses on restoring and expanding the expression of functional dystrophin, a protein essential for muscle cell integrity. The lack of dystrophin in DMD leads to progressive muscle weakness and decline, underscoring the potential impact of this treatment.
EGW-2102 is currently undergoing Phase 1 clinical trials, a critical step in evaluating its safety, tolerability, and preliminary efficacy in patients with DMD. The outcomes of these trials will be pivotal for advancing to subsequent phases of clinical development. If successful, EGW-2102 could not only serve DMD patients but may also be applicable to other muscle disorders characterized by dystrophin deficiency or dysfunction.
In addition to EGW-2102, Edgewise Therapeutics is actively investigating other drug candidates within its pipeline, centralizing its research efforts on conditions that lack effective treatments and are underserved by existing therapeutics.
3. Services:
In its mission to bring new therapies to market, Edgewise Therapeutics provides a range of services that leverage its scientific expertise and proprietary platforms. These services include:
- Drug Discovery and Development: Utilizing advanced methodologies, the company focuses on identifying and developing small molecule candidates targeting muscle disorders. This involves comprehensive screening processes to assess biological activity, selectivity, and other pharmacological properties of potential therapeutic agents.
- Pre-Clinical Research Services: Edgewise conducts rigorous pre-clinical studies to evaluate the efficacy, safety, and pharmacokinetics of their drug candidates. This encompasses both in-vitro assays, which involve testing the compounds in controlled laboratory environments, and in-vivo studies, where the effects of the drugs are observed in live animal models.
- Collaborations and Partnerships: The company actively seeks collaborations with academic institutions and private sector partners to enhance its research capabilities and expand its product pipeline. These partnerships may involve joint ventures in drug development, sharing of technologies, and combined clinical trials.
- Consultative Services: Leveraging its industry knowledge, Edgewise Therapeutics may offer consultative support to other biotechnology and pharmaceutical companies aiming to navigate the complexities of drug development for neuromuscular diseases.
In summary, Edgewise Therapeutics Inc. is dedicated to pioneering small molecule therapies aimed at transforming the treatment landscape for neuromuscular diseases. With EGW-2102 as a central focus and a commitment to collaborative research and development efforts, the company seeks to deliver meaningful advancements that can significantly enhance the lives of patients suffering from debilitating muscle disorders.